POINT Biopharma (PNT) has a large bull flag formation on the daily chart. POINT has 2 therapies in Phase 3 trials that have received fast track designation from the FDA. These means that the FDA will provide expedited review for these therapies. The results for the Phase 3 trials could take place later in 2023. Positive results for the Phase 3 trials would be positive catalysts for the stock to break higher from the bull flag formation.
PNT2002 is for prostate cancer
PNT2003 is for neuroendocrine tumors
POINT has a partnership with Lantheus (LNTH) for these therapies. If these achieve FDA approval, Lantheus will bear the costs of marketing the therapies. Lantheus will pay POINT upfront payments, milestone payments, and royalties on net sales. Of course there is no guarantee that the therapies will achieve FDA approval, but there is reason for optimism as the earlier trials demonstrated efficacy.
https://seekingalpha.com/article/4622010-point-biopharma-stock-has-upcoming-catalysts-with-two-therapies-in-phase-3-trials#comment-95819794
PNT2002 is for prostate cancer
PNT2003 is for neuroendocrine tumors
POINT has a partnership with Lantheus (LNTH) for these therapies. If these achieve FDA approval, Lantheus will bear the costs of marketing the therapies. Lantheus will pay POINT upfront payments, milestone payments, and royalties on net sales. Of course there is no guarantee that the therapies will achieve FDA approval, but there is reason for optimism as the earlier trials demonstrated efficacy.
https://seekingalpha.com/article/4622010-point-biopharma-stock-has-upcoming-catalysts-with-two-therapies-in-phase-3-trials#comment-95819794